Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News vTv Therapeutics Inc VTVT

Healthcare Biotechnology
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of... see more

Recent & Breaking News (NDAQ:VTVT)

vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes

GlobeNewswire December 15, 2020

Aditum Bio Announces Formation of Third Company, Anteris Bio

PR Newswire December 15, 2020

vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio

GlobeNewswire December 15, 2020

vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital

GlobeNewswire November 24, 2020

vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update

GlobeNewswire November 5, 2020

vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study

GlobeNewswire November 4, 2020

vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer's Disease (CTAD) Digital Event

GlobeNewswire October 29, 2020

vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes

GlobeNewswire September 23, 2020

vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual Meeting

GlobeNewswire September 16, 2020

vTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of Directors

GlobeNewswire September 15, 2020

vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update

GlobeNewswire August 3, 2020

vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference

GlobeNewswire July 27, 2020

vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association's Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients

GlobeNewswire June 13, 2020

vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes at the American Diabetes Association's 80th Virtual Scientific Sessions

GlobeNewswire May 27, 2020

vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format

GlobeNewswire May 22, 2020

vTv Therapeutics Announces 2020 First Quarter Financial Results and Update

GlobeNewswire May 7, 2020

vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

GlobeNewswire February 20, 2020

vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes

GlobeNewswire February 10, 2020

vTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 - Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes

GlobeNewswire February 7, 2020

vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

GlobeNewswire December 2, 2019